Drug intelligence / Profile preview

8-(p-sulfophenyl)-theophylline

Development stage
Preclinical
Modality
Small Molecules
Administration
Intravenous, Experimental
01

Overview

8-(p-sulfophenyl)-theophylline is a synthetic, highly water-soluble derivative of theophylline, which belongs to the methylxanthine family.[1][2][3] It acts as a competitive antagonist at adenosine receptors, with notable selectivity for the A2A adenosine receptor subtype (Ki ≈ 57 nM) over A1 (Ki ≈ 3.2 μM), and is essentially inactive at A2B and A3 subtypes at typical concentrations.[1] Its competitive antagonism occurs at the orthosteric binding site, causing functional blockade of adenosine-induced signaling, particularly pathways mediated by Gs and Gi proteins (modulating cAMP and PKA activity).[1] The presence of the p-sulfophenyl group confers strong hydrophilicity and poor blood-brain barrier penetration, meaning it acts predominantly peripherally when administered in vivo. The drug is primarily used as a research tool for investigating peripheral adenosine signaling, cardiovascular pharmacology, and adenosine receptor biology, rather than as a marketed pharmaceutical. It may also modulate phospholipase C-related pathways in relevant tissue models.[1][2]

Other names
8-(p-sulfophenyl)-theophylline8-(4-sulfophenyl)theophyllinePsp-theophylline8-Pspt80206-91-3
02

Targets

ADORA2A (Adenosine A₂A Receptor)ADORA2B (Adenosine A2B receptor)ADORA1 (Adenosine receptor A1 subtype)

Beyond the preview

Go deeper on 8-(p-sulfophenyl)-theophylline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 8-(p-sulfophenyl)-theophylline.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call